Kendle Appoints J. Michael Sprafka, MPH, PhD, Vice President, Kendle Consulting

Industry veteran with extensive experience in pharmacovigilance, outcomes
research and pharmacoeconomics brings strong analytical expertise to lead
growing consulting capability

CINCINNATI, Nov. 2 /PRNewswire-FirstCall/ -- Kendle (Nasdaq: KNDL), a leading,
global full-service clinical research organization, today announced the
appointment of J. Michael Sprafka, MPH, PhD, as Vice President, Kendle
Consulting. Dr. Sprafka will provide leadership for and drive the development
of integrated product development consulting services to help
biopharmaceutical companies accelerate time to market and maximize the
long-term commercial value of their products. His focus will be on delivery
of best-in-class consulting services for customers in the areas of regulatory
affairs and submissions, risk management, epidemiology, pharmacovigilance,
signal detection and safety evaluations, among others. Dr. Sprafka has held
senior leadership roles in the pharmaceutical and government sectors as well
as academia and brings the executive level leadership and analytical expertise
needed to meet increasing customer demands and heightened global regulatory
requirements. He will be based out of Kendle's global headquarters in
Cincinnati and will report to Melanie Bruno, PhD, MBA, Vice President,
Regulatory, Site and Medical Affairs.

"I am delighted to welcome Michael to the Kendle team," said Dr. Bruno. "His
extensive and diverse experience will significantly enhance our ability to
deliver best-in-class regulatory consulting services and risk management
capabilities to our customers across Phase I through IV clinical development
and beyond. As our customers' products move through the product life cycle,
Kendle's Consulting team can assist in conducting sophisticated analyses from
ongoing data sources to gain a greater understanding of side effects and
adverse events and best reflect the products' safety for the patient."

The addition of Dr. Sprafka strengthens Kendle Consulting, a growing area of
the Company dedicated to working with biopharmaceutical companies to optimize
their clinical development planning, understand and minimize risk and manage
product development and monitoring throughout the product lifecycle. By
combining the cumulative expertise of Kendle's broad spectrum of clinical
development services, Kendle Consulting matches thought leadership with the
specific needs of our customers to maximize the value of their portfolios.

Dr. Sprafka is an epidemiologist with extensive expertise in
pharmacovigilance, outcomes research and pharmacoeconomics. He has more than
15 years of senior leadership experience, having served most recently as
Senior Director, Pharmacovigilance, Epidemiology and Pharmacoeconomics for
Procter & Gamble Pharmaceuticals. Dr. Sprafka also has served as Associate
Professor of Epidemiology at the University of Minnesota and as an
Epidemiologist at the Minnesota Department of Health. He holds a Bachelor of
Arts in biology, a Master of Science in environmental health, a Master of
Public Health in epidemiology and a Doctorate in epidemiology from the
University of Minnesota.

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research
organization providing the full range of early- to late-stage clinical
development services for the world's biopharmaceutical industry. Our focus is
on innovative solutions that reduce cycle times for our customers and
accelerate the delivery of life-enhancing drugs to market for the benefit of
patients worldwide. As one of the world's largest global providers of Phase
I-IV services, we offer experience spanning more than 100 countries, along
with industry-leading patient access and retention capabilities and broad
therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from
Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's
Web site at www.kendle.com.

SOURCE Kendle International Inc.

Michael Lawson, Investors, +1-513-763-1992 , Lori Dorer, Media,
+1-513-345-1685, both of Kendle International Inc.